Impact of Two Guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation.

Fibrin Blood Clot Clinical Trial

Official title:

Impact of Two Thromboelastometry-guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation. a Multicenter, Randomized Trial. TROMBOFIBtrial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04405518
• Other study ID #: TROMBOFIBtrial
• Secondary ID: 2018-002510-13
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: June 17, 2019
• Est. completion date: October 31, 2022

Study information

• Verified date: November 2021
• Source: Hospital Universitari de Bellvitge
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a national multicentre clinical study, where 3 hospitals are involved: Bellvitge University Hospital, Clinic Hospital of Barcelona and Cruces Hospital of Bilbao). It is a randomized study based on the Hemoglobin value of the patient with a 1:1 ratio, parallel groups, controlled and single blind, in patients undergoing an orthotopic liver transplant, confirming previously that the participants fulfill all the inclusion criteria and none of exclusion.

Description:

A total of 176 patients will be included (88 per group) and each center can not include more than 40% of the sample to avoid bias.

Blood samples will be analyzed at different times of the surgical intervention by an electronic device called thromboelastogram. It evaluates the blood clot characteristics and, depending on the results, assesses the need to correct values by the administration of fibrinogen or platelets.

One of the coagulation parameter evaluated and corrected by thromboelastogram is called A10FIBTEM. In a previous study, the investigators have seen that maintaining some specific ranges in the A10FIBTEM, results in a decrease of the use of blood products. That's why the investigators have created 2 groups:

• The control group will be corrected up to a value of A10FIBTEM = 8mm.

• The intervention group will be corrected up to a value of A10FIBTEM = 11mm.

Subsequently, results between groups will be compared. The investigators have to consider that the drug used in this study (Riastap) is an authorized and commercial drug.

The main objective is to demonstrate that the administration of fibrinogen in the intervention group compared to the control group changes the administration of red blood cells pack during the liver transplant and in the first 24 hours after.

Secondary objectives consist in demonstrate that in the intervention group, there is also a change in the administration of other blood products, a change in acute renal damage, a change in hours of mechanical ventilation, no changes in thrombotic events in the hepatic graft or in the patient in the first 90 days of the liver transplant and no changes in re operations, re-transplantation, or mortality during the first 90 days of the liver transplant, compared to the control group.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 188
• Est. completion date: October 31, 2022
• Est. primary completion date: November 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age > 18 years.

• Candidate to an orthotopic liver trasnplantation.

• Informed consent.

• Preoperative hemoglobine </= 130 g/L

Exclusion Criteria:

• Preoperative hemoglobin> 130 g / L

• Familial amyloid polyneuropathy

• Polycystosis hepatic

• Living donor liver transplant

• Uncontrolled donor after cardiac death

• Acute / subacute liver failure

• Re-transplant (in the same hospital admission)

• Use of Anticoagulation drugs before transplantation.

• Age <18 years.

• Pregnancy and lactation.

Related Conditions & MeSH terms

• Fibrin Blood Clot
• Thrombosis

Intervention

Drug:
• Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.

Locations

Country	Name	City	State
Spain	Clinic Hospital	Barcelona
Spain	Cruces Hospital	Bilbao	Vizcaya
Spain	Bellvitge Universitary Hospital	Hospitalet de Llobregat	Barcelone

Sponsors (1)

Lead Sponsor	Collaborator
Antoni Sabaté Pes

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the rate of red blood cell packs transfusion during procedure and in the first 24hours after between groups.	Demonstrate that the A10FIBTEM correction with the administration of fibrinogen up to an A10FIBTEM value of 11mm, change the administration of red blood cell pack during the procedure and in the first 24 hours after it, comparing to the administration of fibrinogen up to an A10FIBTEM of 8mm.	Intraoperative and the first 24 hours after surgery.
Secondary	Evaluation of the rate of other blood products between groups.	Demonstrate that the A10FIBTEM correction with the administration of fibrinogen up to an A10 FIBTEM value of 11mm change the administration of platelets, frozen fresh plasma and other blood products.	Intraoperative and the first 24 hours after surgery.
Secondary	Evaluation of the acute kidney injury between groups using the Kidney Disease Improving Global Outcomes scale,the minimum values is 1 and the maximum values is 3, higher scores mean a worse outcome.	Demonstrate that the A10FIBTEM correction with the administration of fibrinogen up to an A10 FIBTEM value of 11mm change the kidney injury through study completion	first week after the procedure and until 90 days after the procedure.
Secondary	Evaluation of the duration of mechanical ventilation in hours between groups.	Demonstrate that the A10FIBTEM correction with the administration of fibrinogen up to an A10 FIBTEM value of 11mm change the need of mechanical ventilation through study completion (comparing the number of hours of mechanical ventilation of each group).	first week after the procedure and until 90 days after the procedure..
Secondary	Number of participants with major advers cardiac events (MACE), Number of participants with, any sign of infection, Number of participants with neurological events through study completion	Demonstrate that the A10FIBTEM correction with the administration of fibrinogen up to an A10 FIBTEM value of 11mm change the Number of participants with any adverse events.	Until 90 days after the procedure.
Secondary	Number of participants with thrombotic events in the hepatic graft measured by ecodoppler assessment; and the number of participants with any other thrombotic events measured by ecodoppler assessment of leg extremity or tomography axial of the lungs	Demonstrate that the A10FIBTEM correction with the administration of fibrinogen up to an A10 FIBTEM value of 11mm do not change thrombotic events in the hepatic graft or in the patient.	Until 90 days after procedure
Secondary	Number of participants who require reoperation for any cause; Number of participants who require being re transplanted and number of participant who died through the study completion	Demonstrate that the A10FIBTEM correction with the administration of fibrinogen up to an A10 FIBTEM value of 11mm do not change the outcome related to reoperation, re-transplantations or mortality.	Until 90 days after procedure